Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | OTC | P00480 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | ARG2 | P78540 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL18149039 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL18149040 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL19181970 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL22207237 | 1.00 | GSR (0.59) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL8957537 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL714211 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL3516723 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL11660904 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL15022773 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL4954180 | 0.95 | GSR (0.65) | GSROTCGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934572-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| CN-109867726-B | Fusion protein and application thereof | 华南师范大学 | 2021-01-15 | — | — | CN | disclosed |
| US-20190203248-A1 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| CN-109867726-A | A kind of fusion protein and its application | 华南师范大学 | 2019-06-11 | — | — | CN | disclosed |
| US-10221438-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-05 | — | — | US | disclosed |
| US-20190031722-A1 | INTERVENTIONS FOR FLAVIVIRUS INFECTIONS | IOGENETICS, LLC | 2019-01-31 | — | — | US | disclosed |
| CN-107698682-A | Seralbumin binding molecule | 百时美施贵宝公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2017132210-A1 | INTERVENTIONS FOR FLAVIVIRUS INFECTIONS | IOGENETICS, LLC (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170145464-A1 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-25 | — | — | US | disclosed |
| US-9540424-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3083662-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXIGENASE (PAM) FOR C-TERMINAL AMIDATION | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| CN-103003301-B | Serum albumin binding molecules | 百时美施贵宝公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-105793278-A | Use of peptidylglycine alpha amidating monooxygenase (PAM) for C-terminal amidation | 豪夫迈·罗氏有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2015091131-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXIGENASE (PAM) FOR C-TERMINAL AMIDATION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150152147-A1 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-04 | — | — | US | disclosed |
| US-8969289-B2 | Serum albumin binding molecules | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2566888-A2 | SERUM ALBUMIN BINDING MOLECULES | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140086-A9 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110305663-A1 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140086-A2 | SERUM ALBUMIN BINDING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145464-A1 | SERUM ALBUMIN BINDING MOLECULES | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
| US-20110305663-A1 | SERUM ALBUMIN BINDING MOLECULES | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
| US-20150152147-A1 | SERUM ALBUMIN BINDING MOLECULES | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
| US-10934572-B2 | Serum albumin binding molecules | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
| US-20190203248-A1 | SERUM ALBUMIN BINDING MOLECULES | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
| US-10221438-B2 | Serum albumin binding molecules | FN1, ALB, FABP3 | GSR 4810/4885OTC 4853/4885GNAI3 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.